계명대학교 의학도서관 Repository

A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer

Metadata Downloads
Author(s)
김진영도영록박건욱송홍석
Alternative Author(s)
Kim, Jin YoungDo, Young RokPark, Keon UkSong, Hong Suk
Issued Date
2010
Abstract
Objective : The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer.
Methods : Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m2 and cisplatin 70 mg/m2 were intravenously given on day 1 of 21 days schedule.
Results : From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients.
Conclusion : Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer.
Keywords : Esophageal cancer – Docetaxel – Cisplatin – Combination chemotherapy
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Cancer Chemotherapy and Pharmacology, Vol.66(1) : 31-36, 2010
Type
Article
ISSN
0344-5704
DOI
10.1007/s00280-009-1130-6
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35286
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.